Xellsmart, a stem-cell startup headquartered in Suzhou, has announced that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its induced pluripotent stem cell (iPSC) derived subtype neural precursor cell therapy, targeting amyotrophic lateral sclerosis (ALS).
ALS is a devastating motor neuron disease and progressive neurodegenerative condition characterized by the continuous degeneration and death of the patient’s motor neurons. The average survival time for patients with ALS is a mere 39 months, and at present, there is no effective treatment available to combat this disease.- Flcube.com
